The study, which examined data from nearly 50,000 hospital admissions between April and November 2021, found that the vaccine was 94% effective at preventing hospitalization 50-100 days after receiving the injection but fell to 80.4% 200-250 days later, with a more pronounced decline. fast again after 250 days.
READ ALSO – Health Office Says 1,271,479 People in Jakarta Have Booster Vaccinations
In addition to examining vaccine effectiveness over time, the Providence study was also able to identify factors associated with decreased vaccine effectiveness.
The main risk factors for severe “breakthrough” infections include advanced age (80+), co-morbidities such as cancer, transplant, chronic kidney disease, hypertension, or heart failure, the amount of time that has passed since being vaccinated, and the type of illness. received vaccines.
For the last factor, the study found that Moderna’s vaccine offered the best overall protection over time, whereas Pfizer-BioNTech’s vaccine offered similar initial protection to Moderna but decreased more rapidly over time.
People who received the Janssen vaccine also had a higher chance of developing a severe breakthrough infection compared to Moderna.
“These data help us understand differences in waning protection by vaccine type. Unlike most other studies, our data spanned more than six months, during which we found evidence of rapidly diminishing protection, particularly for patients 80 years of age or older,” said Amy Compton-Phillips, MD, Providence’s chief clinical officer. from Medical Xpress, Sunday (27/2/2022).
The Providence study, one of the largest of its kind, demonstrates the value of connecting a network of researchers with large-scale healthcare data to help health systems, public health agencies, policymakers, and patients and community members learn and react i lmore quickly to emergencies or endemic health challenges.
(wbs)
–
